Evidence map›Paper›PMID 39589495›Full record

ArticleAnnals of hematology2025

Copy number alterations in pediatric B-cell precursor acute lymphoblastic leukemia patients and their association with patients' outcome.

Nesma E Abdelfattah, Ghada M Elsayed, Amira H Soliman, Emad N Ebeid, Mona S El Ashry

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nesma E AbdelfattahClinical Pathology Department, National Cancer Institute, Cairo University, Kasr Al Eini Street, 4 Form El Khalig, Cairo, 11796, Egypt. Nesmaelsayed@cu.edu.eg.ORCID https://orcid.org/0009-0003-2893-0744
Ghada M ElsayedClinical Pathology Department, National Cancer Institute, Cairo University, Kasr Al Eini Street, 4 Form El Khalig, Cairo, 11796, Egypt.
Amira H SolimanClinical Pathology Department, National Cancer Institute, Cairo University, Kasr Al Eini Street, 4 Form El Khalig, Cairo, 11796, Egypt.
Emad N EbeidPediatric Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
Mona S El AshryClinical Pathology Department, National Cancer Institute, Cairo University, Kasr Al Eini Street, 4 Form El Khalig, Cairo, 11796, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Genetic abnormalities provide diagnostic and prognostic information for pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL) patients. The aim of this study was to determine the effects of genetic CNAs and RUNX1 gene abnormalities on the outcome of pediatric BCP-ALL patients. This study included 78 de novo-BCP-ALL pediatric patients who presented to the Pediatric Oncology Department of the National Cancer Institute (NCI), Cairo University. We aimed to study the impact of copy number alteration (CNA) of 8 of the most altered genes in BCP-ALL patients, in addition to RUNX1 gene abnormalities, on patient survival and response to treatment. Multiplex ligation-dependent probe amplification (MLPA) was used to detect CNA, while RUNX1 gene alterations were detected by fluorescence in situ hybridization (FISH). CNA of the PAX5 gene was significantly associated with worse overall survival (OS) and event-free survival (EFS) (P = 0.012 and P = 0.025, respectively). An increase in the CNA of ETV6 was associated with an increase in minimal residual disease (MRD) on day 15 (P = 0.041). Although RUNX1 gene abnormalities were not a predictor of shorter OS or EFS, an interesting significant association was found between PAX5 CNA and RUNX1 gene gain and translocation (P = 0.017 and P = 0.041, respectively). PAX5 CNA is an adverse prognostic factor. ETV6 CNA is associated with high MRD on day 15.

Indexed as

DNA Copy Number VariationsPrecursor B-Cell Lymphoblastic Leukemia-LymphomaAdolescentChildChild, PreschoolCore Binding Factor Alpha 2 SubunitDisease-Free SurvivalETS Translocation Variant 6 ProteinFemaleHumansInfantMaleNeoplasm, ResidualPAX5 Transcription FactorPrognosisProto-Oncogene Proteins c-etsCore Binding Factor Alpha 2 SubunitETS Translocation Variant 6 ProteinPAX5 protein, humanPAX5 Transcription FactorProto-Oncogene Proteins c-etsRepressor ProteinsRUNX1 protein, humanALLBCP-ALLFISHMLPAPAX5RUNX1

Identifiers

PMID39589495
PMCPMC12031935

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.